Bionomics Limited (BNO) was a biopharmaceutical company focused on the discovery and development of novel drug candidates focused on the treatment of central nervous system disorders such as anxiety, depression and Alzheimer's Disease.
Bionomics was delisted from the ASX on request on 28/8/23.
|
NEW ROLE: Connor Bernstein, . | 01 Mar 2022 |
|
|
NEW ROLE: Liz Doolin, . | 25 Aug 2021 |
|
NEW ROLE: Suzanne Irwin, Company Secretary | 11 Aug 2021 |
|
|
NEW ROLE: Miles Davies, Non-Executive Director | 11 Aug 2021 |
|
|
NEW ROLE: Jens Mikkelsen, . | 24 Nov 2020 |
|
|
NEW ROLE: Stephen Birrell, Chief Financial Officer | 24 Nov 2020 |
|
|
NEW ROLE: Adrian Hinton, Chief Financial Officer | 24 Nov 2020 |
|
|
NEW ROLE: Paul Rolan, Chief Medical Officer | 24 Nov 2020 |
|
NEW ROLE: Steven Lydeamore, Chief Financial Officer | 24 Nov 2020 |
